Titan Pharmaceuticals Inc - Asset Resilience Ratio
Titan Pharmaceuticals Inc (TTNP) has an Asset Resilience Ratio of 3.05% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2017)
This chart shows how Titan Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Titan Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Titan Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Titan Pharmaceuticals Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $361.00K | 3.05% |
| Total Liquid Assets | $361.00K | 3.05% |
Asset Resilience Insights
- Limited Liquidity: Titan Pharmaceuticals Inc maintains only 3.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Titan Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Titan Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Titan Pharmaceuticals Inc (2000–2017)
The table below shows the annual Asset Resilience Ratio data for Titan Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 4.05% | $361.00K | $8.90 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $18.67 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $13.29 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $20.85 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $18.42 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $10.22 Million | -- |
| 2008-12-31 | 62.68% | $3.57 Million | $5.70 Million | +48.41pp |
| 2007-12-31 | 14.27% | $4.40 Million | $30.84 Million | -13.00pp |
| 2006-12-31 | 27.27% | $4.10 Million | $15.04 Million | -14.41pp |
| 2005-12-31 | 41.68% | $8.23 Million | $19.74 Million | -38.21pp |
| 2004-12-31 | 79.89% | $30.86 Million | $38.63 Million | -1.16pp |
| 2003-12-31 | 81.05% | $39.72 Million | $49.01 Million | -6.26pp |
| 2002-12-31 | 87.32% | $66.30 Million | $75.93 Million | -5.35pp |
| 2001-12-31 | 92.67% | $99.28 Million | $107.13 Million | +10.58pp |
| 2000-12-31 | 82.08% | $97.22 Million | $118.44 Million | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.